Healthcare

Meet your Healthcare Research team

CVS Group

Non-core disposals

CVS has announced the disposal of its non-core and loss-making operations in The Netherlands and Ireland for a nominal sum. This enables the company to focus on its key UK market and...

hVIVO

FY2023 results

hVIVO made significant progress in 2023 with multiple challenge contracts signed and a record number of volunteers inoculated. Top-line growth of 16% drove margin expansion and led to...

Uniphar

Focus on the target

We believe that the headwinds that held back Uniphar’s stock in 2022-2023 are now in the past. The outlook is far more positive. We estimate that achieving its medium-term EBITDA...

CVS Group

CMA provisionally launching a formal market investigation

The Competition and Markets Authority (CMA) announced yesterday (March 12th) that its initial review into the vets market has identified multiple concerns. It has provisionally launched...

CVS Group

H1 2024 results reflect another period of good growth

Following the trading statement on January 25th, CVS has reported interim results to December 31st that reflect strong like-for-like top-line growth and an EBITDA margin of 19.1%, both...

Uniphar

FY2023 results reflect strong organic gross profit growth

Uniphar’s FY2023 results reflect strong organic growth in gross profits of 5.6% year-on-year (yoy). Adjusted EBITDA expanded 18% yoy. Higher interest costs and depreciation charges...

hVIVO

Trading update

hVIVO’s trading update for the year ending December 31st reflects stronger than expected results driven by strong margins. The outlook for 2024 is very positive with 90% revenue...

Uniphar

Trading statement

Uniphar’s trading statement to the end December 31st highlights a strong year of operating results. We are maintaining our forecasts. The outlook for 2024 is very positive and we...

Malin Corporation

CG Oncology IPO drives NAV growth

Malin has announced that one of its investments, CG Oncology, will list on the NASDAQ today following its initial public offering (IPO). Based on pricing, the value of the group’s existing...

CVS Group

H1 2024 trading statement

CVS has reported strong revenue growth of 11.4% year-on-year (yoy) and an EBITDA margin of 19.0% in its trading statement for H1 2024 to December 31st. These figures are in line with...